Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial
This study demonstrated that NVX-CoV2373 produced consistent immunogenicity responses to SARS-CoV-2 among PLWH and HIV-uninfected participants, with no new safety signals.
Authors
- Anthonet Koen
- Faeezah Patel (ORCID: https://orcid.org/0000-0003-1503-2016)
- Chijioke Bennett
- Zaheer Hoosain
- Gabriella Benadé
- Umesh Lalloo
- Shirley Galbiati
- Shabir Ahmed Madhi (ORCID: https://orcid.org/0000-0002-7629-0636)
- Vongane Louisa Maluleke
- Vivek Shinde
- Esme Louise Venter
- Cheryl Louw
Institutions
- Mercer (Czechia) (CZ)
- South African Medical Research Council (ZA)
- Durban University of Technology (ZA)
- University of the Witwatersrand (ZA)
- Novavax (United States) (US)
- Aurum Institute (ZA)
- Clinvet (ZA)
- Museum of Arts and Design (US)
Publication Details
- Journal
- Journal of Infection
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1016/j.jinf.2024.106285
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Novavax